Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 12/20 | 0.74 |
| ▸ | UBA3 | Q8TBC4 | 12/20 | 0.74 |
| ▸ | PRMT5 | O14744 | 8/20 | 0.51 |
| ▸ | SAE1 | Q9UBE0 | 6/20 | 0.48 |
| ▸ | UBA2 | Q9UBT2 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL783760 | 1.00 | NAE1 (0.74) | NAE1UBA3PRMT5SAE1UBA2 | |
| SCHEMBL18540617 | 0.88 | NAE1 (0.57) | NAE1UBA3PRMT5 | |
| SCHEMBL783875 | 0.82 | NAE1 (0.72) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL783607 | 0.79 | NAE1 (0.65) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL782912 | 0.79 | NAE1 (0.76) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL783185 | 0.77 | NAE1 (0.67) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL783677 | 0.77 | NAE1 (0.62) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL783500 | 0.76 | NAE1 (0.72) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL783720 | 0.76 | NAE1 (0.83) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL2349713 | 0.74 | NAE1 (0.70) | NAE1UBA3SAE1UBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008307-B2 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20080051404-A1 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051404-A1 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | RCE1, ECE1, UBE2E1 | NAE1 24/4885UBA3 6/4885PRMT5 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.